A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001 (NCT00795639)
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Sildenafil (Primary) ; Sitaxentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 12 May 2014 New trial record
- 18 Apr 2011
- 08 Mar 2011